GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Intangible Assets

PRME (Prime Medicine) Intangible Assets : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Prime Medicine's intangible assets for the quarter that ended in Dec. 2024 was $0.00 Mil.


Prime Medicine Intangible Assets Historical Data

The historical data trend for Prime Medicine's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Intangible Assets Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Intangible Assets
- - - - -

Prime Medicine Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Prime Medicine Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Prime Medicine  (NAS:PRME) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Prime Medicine Intangible Assets Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Prime Medicine Business Description

Traded in Other Exchanges
N/A
Address
60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson officer: See Remarks 88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser officer: SVP, Strategy & Corporate Ops. PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield officer: Chief Scientific Officer PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139